-+ 0.00%
-+ 0.00%
-+ 0.00%

Needham Maintains Buy on Cartesian Therapeutics, Lowers Price Target to $40

Benzinga·05/26/2026 16:32:04
Listen to the news
Needham analyst Gil Blum maintains Cartesian Therapeutics (NASDAQ:RNAC) with a Buy and lowers the price target from $42 to $40.